QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

Home
/
update
/
details

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

NextEdge Admin

13 Jan 2025

2 min 30 sec

ADC Technology,Synaffix,Cancer Therapies

Boehringer Ingelheim has licensed Synaffix B.V.'s (a Lonza company) antibody-drug conjugate (ADC) technology, strengthening its oncology portfolio through its subsidiary, NBE Therapeutics. This collaboration aims to develop next-generation cancer treatments by combining Boehringer’s expertise with Synaffix’s clinically validated ADC platform.

ADCs are an innovative class of therapies that merge the precision of antibodies with the potency of cytotoxic drugs, ensuring targeted cancer cell destruction while minimizing harm to healthy tissue. Synaffix’s platform utilizes enzymatic glycan modification to enhance ADC efficacy, allowing for best-in-class ADC or bispecific development.

Peter van de Sande, Head of Synaffix, emphasized that Boehringer's adoption of their ADC technology validates its potential to optimize therapeutic outcomes. Lamine Mbow, Boehringer’s Global Head of Discovery Research, highlighted the company’s focus on developing a broad ADC pipeline targeting novel tumor spaces to improve cancer patient outcomes.

The agreement grants Boehringer access to Synaffix’s proprietary ADC technology for multiple targets, with the first target selected at signing. Additional targets will be nominated within a defined timeframe. The deal includes an upfront payment, potential milestone payments up to $1.3 billion, and royalties on net sales of resulting products.

Synaffix’s ADC platform, featuring GlycoConnect™, HydraSpace®, and toxSYN® technologies, enables rapid clinical development through an established supply chain and strong patent protection. Its business model revolves around target-specific technology out-licensing, as demonstrated by its growing partnered pipeline.

This partnership enhances Boehringer’s ability to address high unmet needs in oncology by advancing first-in-class ADC therapies, reinforcing its commitment to transforming cancer treatment.